61 related articles for article (PubMed ID: 21550400)
1. Development and physico-chemical characterization of a liposomal formulation of istaroxime.
Luciani P; Fevre M; Leroux JC
Eur J Pharm Biopharm; 2011 Oct; 79(2):285-93. PubMed ID: 21550400
[TBL] [Abstract][Full Text] [Related]
2. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method.
Qiu L; Jing N; Jin Y
Int J Pharm; 2008 Sep; 361(1-2):56-63. PubMed ID: 18573626
[TBL] [Abstract][Full Text] [Related]
3. The encapsulation and release of guanosine from PEGylated liposomes.
Er Y; Barnes TJ; Fornasiero D; Prestidge CA
J Liposome Res; 2009; 19(1):29-36. PubMed ID: 19515005
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of doxorubicin liposomes.
Niu G; Cogburn B; Hughes J
Methods Mol Biol; 2010; 624():211-9. PubMed ID: 20217598
[TBL] [Abstract][Full Text] [Related]
5. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies.
Li C; Cui J; Wang C; Zhang L; Xiu X; Li Y; Wei N; Li Y; Zhang L
J Pharm Pharmacol; 2011 Mar; 63(3):376-84. PubMed ID: 21749385
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines.
Erdoğ A; Putra Limasale YD; Keskin D; Tezcaner A; Banerjee S
J Pharm Sci; 2013 Oct; 102(10):3666-77. PubMed ID: 23897281
[TBL] [Abstract][Full Text] [Related]
7. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
[TBL] [Abstract][Full Text] [Related]
8. Solubilisation of drugs within liposomal bilayers: alternatives to cholesterol as a membrane stabilising agent.
Ali MH; Kirby DJ; Mohammed AR; Perrie Y
J Pharm Pharmacol; 2010 Nov; 62(11):1646-55. PubMed ID: 21039548
[TBL] [Abstract][Full Text] [Related]
9. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system.
Tagami T; Ernsting MJ; Li SD
J Control Release; 2011 Sep; 154(3):290-7. PubMed ID: 21640149
[TBL] [Abstract][Full Text] [Related]
10. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery.
Maestrelli F; González-Rodríguez ML; Rabasco AM; Mura P
Int J Pharm; 2006 Apr; 312(1-2):53-60. PubMed ID: 16469460
[TBL] [Abstract][Full Text] [Related]
11. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
12. Liposomal drugs dispersed in hydrogels. Effect of liposome, drug and gel properties on drug release kinetics.
Mourtas S; Fotopoulou S; Duraj S; Sfika V; Tsakiroglou C; Antimisiaris SG
Colloids Surf B Biointerfaces; 2007 Apr; 55(2):212-21. PubMed ID: 17223020
[TBL] [Abstract][Full Text] [Related]
13. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
Demirgöz D; Garg A; Kokkoli E
Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
[TBL] [Abstract][Full Text] [Related]
14. Complementary liposomes based on phosphatidylcholine: interaction effectiveness vs protective coating.
Pantos A; Sideratou Z; Paleos CM
J Colloid Interface Sci; 2002 Sep; 253(2):435-42. PubMed ID: 16290875
[TBL] [Abstract][Full Text] [Related]
15. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin.
Dicko A; Kwak S; Frazier AA; Mayer LD; Liboiron BD
Int J Pharm; 2010 May; 391(1-2):248-59. PubMed ID: 20156541
[TBL] [Abstract][Full Text] [Related]
16. Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery.
Li W; Huang Z; MacKay JA; Grube S; Szoka FC
J Gene Med; 2005 Jan; 7(1):67-79. PubMed ID: 15515149
[TBL] [Abstract][Full Text] [Related]
17. A synthetic method for peptide-PEG-lipid conjugates: application of octreotide-PEG-DSPE synthesis.
Su JC; Tseng CL; Chang TG; Yu WJ; Wu SK
Bioorg Med Chem Lett; 2008 Aug; 18(16):4593-6. PubMed ID: 18656351
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery.
Heyes J; Hall K; Tailor V; Lenz R; MacLachlan I
J Control Release; 2006 May; 112(2):280-90. PubMed ID: 16603272
[TBL] [Abstract][Full Text] [Related]
19. Istaroxime: a new luso-inotropic agent for heart failure.
Mattera GG; Lo Giudice P; Loi FM; Vanoli E; Gagnol JP; Borsini F; Carminati P
Am J Cardiol; 2007 Jan; 99(2A):33A-40A. PubMed ID: 17239702
[TBL] [Abstract][Full Text] [Related]
20. Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes.
Tang WL; Tang WH; Chen WC; Diako C; Ross CF; Li SD
Mol Pharm; 2017 Jun; 14(6):1969-1979. PubMed ID: 28460165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
